439 related articles for article (PubMed ID: 32864784)
41. Clinical Implications of SARS-CoV-2 Interaction With Renin Angiotensin System: JACC Review Topic of the Week.
Brojakowska A; Narula J; Shimony R; Bander J
J Am Coll Cardiol; 2020 Jun; 75(24):3085-3095. PubMed ID: 32305401
[TBL] [Abstract][Full Text] [Related]
42. Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial.
Bauer A; Schreinlechner M; Sappler N; Dolejsi T; Tilg H; Aulinger BA; Weiss G; Bellmann-Weiler R; Adolf C; Wolf D; Pirklbauer M; Graziadei I; Gänzer H; von Bary C; May AE; Wöll E; von Scheidt W; Rassaf T; Duerschmied D; Brenner C; Kääb S; Metzler B; Joannidis M; Kain HU; Kaiser N; Schwinger R; Witzenbichler B; Alber H; Straube F; Hartmann N; Achenbach S; von Bergwelt-Baildon M; von Stülpnagel L; Schoenherr S; Forer L; Embacher-Aichhorn S; Mansmann U; Rizas KD; Massberg S;
Lancet Respir Med; 2021 Aug; 9(8):863-872. PubMed ID: 34126053
[TBL] [Abstract][Full Text] [Related]
43. Overexpression of the Severe Acute Respiratory Syndrome Coronavirus-2 Receptor, Angiotensin-Converting Enzyme 2, in Diabetic Kidney Disease: Implications for Kidney Injury in Novel Coronavirus Disease 2019.
Gilbert RE; Caldwell L; Misra PS; Chan K; Burns KD; Wrana JL; Yuen DA
Can J Diabetes; 2021 Mar; 45(2):162-166.e1. PubMed ID: 32917504
[TBL] [Abstract][Full Text] [Related]
44. The renin-angiotensin-aldosterone system inhibitors in COVID-19: from acidosis to ventilation and immunity.
Liao WH; Yang GG; Henneberg M
Swiss Med Wkly; 2020 Nov; 150():w20444. PubMed ID: 33306813
[No Abstract] [Full Text] [Related]
45. Effect of Renin-Angiotensin-Aldosterone System Inhibitors in Patients with COVID-19: a Systematic Review and Meta-analysis of 28,872 Patients.
Baral R; White M; Vassiliou VS
Curr Atheroscler Rep; 2020 Aug; 22(10):61. PubMed ID: 32830286
[TBL] [Abstract][Full Text] [Related]
46. Renin-angiotensin system and SARS-CoV-2 interaction: underlying mechanisms and potential clinical implications.
Hrenak J; Zorad S; Simko F
Gen Physiol Biophys; 2020 May; 39(3):203-204. PubMed ID: 32525813
[TBL] [Abstract][Full Text] [Related]
47. Therapy With Agents Acting on the Renin-Angiotensin System and Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
Gnavi R; Demaria M; Picariello R; Dalmasso M; Ricceri F; Costa G
Clin Infect Dis; 2020 Nov; 71(16):2291-2293. PubMed ID: 32442294
[TBL] [Abstract][Full Text] [Related]
48. Cardiovascular Pharmacology in the Time of COVID-19: A Focus on Angiotensin-Converting Enzyme 2.
Buckley LF; Cheng JWM; Desai A
J Cardiovasc Pharmacol; 2020 Jun; 75(6):526-529. PubMed ID: 32301766
[TBL] [Abstract][Full Text] [Related]
49. Lock, Stock and Barrel: Role of Renin-Angiotensin-Aldosterone System in Coronavirus Disease 2019.
Zanza C; Tassi MF; Romenskaya T; Piccolella F; Abenavoli L; Franceschi F; Piccioni A; Ojetti V; Saviano A; Canonico B; Montanari M; Zamai L; Artico M; Robba C; Racca F; Longhitano Y
Cells; 2021 Jul; 10(7):. PubMed ID: 34359922
[TBL] [Abstract][Full Text] [Related]
50. COVID-19 and Cardiovascular Disease: From Bench to Bedside.
Chung MK; Zidar DA; Bristow MR; Cameron SJ; Chan T; Harding CV; Kwon DH; Singh T; Tilton JC; Tsai EJ; Tucker NR; Barnard J; Loscalzo J
Circ Res; 2021 Apr; 128(8):1214-1236. PubMed ID: 33856918
[TBL] [Abstract][Full Text] [Related]
51. Renin-angiotensin system inhibition and risk of infection and mortality in COVID-19: a systematic review and meta-analysis.
Koshy AN; Murphy AC; Farouque O; Ramchand J; Burrell LM; Yudi MB
Intern Med J; 2020 Dec; 50(12):1468-1474. PubMed ID: 33191600
[TBL] [Abstract][Full Text] [Related]
52. Modeling the Molecular Impact of SARS-CoV-2 Infection on the Renin-Angiotensin System.
Pucci F; Bogaerts P; Rooman M
Viruses; 2020 Nov; 12(12):. PubMed ID: 33265982
[TBL] [Abstract][Full Text] [Related]
53. Overexpression of angiotensin-converting enzyme 2 by renin-angiotensin system inhibitors. Truth or myth? A systematic review of animal studies.
Kai H; Kai M; Niiyama H; Okina N; Sasaki M; Maeda T; Katoh A
Hypertens Res; 2021 Aug; 44(8):955-968. PubMed ID: 33750913
[TBL] [Abstract][Full Text] [Related]
54. Double trouble: combined cardiovascular effects of particulate matter exposure and coronavirus disease 2019.
Tanwar V; Adelstein JM; Wold LE
Cardiovasc Res; 2021 Jan; 117(1):85-95. PubMed ID: 33084879
[TBL] [Abstract][Full Text] [Related]
55. Severe acute respiratory syndrome coronavirus 2 and renin-angiotensin system blockers: A review and pooled analysis.
Kerneis M; Ferrante A; Guedeney P; Vicaut E; Montalescot G
Arch Cardiovasc Dis; 2020 Dec; 113(12):797-810. PubMed ID: 33199208
[TBL] [Abstract][Full Text] [Related]
56. Statins in COVID-19: is there any foundation?
Lima Martínez MM; Contreras MA; Marín W; D'Marco L
Clin Investig Arterioscler; 2020; 32(6):278-281. PubMed ID: 32718669
[TBL] [Abstract][Full Text] [Related]
57. Developing new drugs that activate the protective arm of the renin-angiotensin system as a potential treatment for respiratory failure in COVID-19 patients.
Latil M; Camelo S; Veillet S; Lafont R; Dilda PJ
Drug Discov Today; 2021 May; 26(5):1311-1318. PubMed ID: 33609783
[TBL] [Abstract][Full Text] [Related]
58. A comparison between virus- versus patients-centred therapeutic attempts to reduce COVID-19 mortality.
Camelo S; Latil M; Agus S; Dioh W; Veillet S; Lafont R; Dilda PJ
Emerg Microbes Infect; 2021 Dec; 10(1):2256-2263. PubMed ID: 34783636
[TBL] [Abstract][Full Text] [Related]
59. Role of Hypertension on the Severity of COVID-19: A Review.
Peng M; He J; Xue Y; Yang X; Liu S; Gong Z
J Cardiovasc Pharmacol; 2021 Nov; 78(5):e648-e655. PubMed ID: 34321401
[TBL] [Abstract][Full Text] [Related]
60. A potential therapeutic combination for treatment of COVID-19: Synergistic effect of DPP4 and RAAS suppression.
Phyu Khin P; Cha SH; Jun HS; Lee JH
Med Hypotheses; 2020 Nov; 144():110186. PubMed ID: 33254506
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
